AstraZeneca

AstraZeneca's Imfinzi approved by FDA for limited-stage small cell lung cancer, reducing death risk by 27% in Adriatic trial. Imfinzi is now the only immunotherapy approved for both limited- and extensive-stage small cell lung cancer.

FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer (LS-SCLC) post-chemotherapy and radiation. Supported by ADRIATIC trial results, Imfinzi improves median overall survival to 22.5 months, marking a new benchmark in treatment.

FDA approves durvalumab (Imfinzi) for limited-stage small cell lung cancer (SCLC) post-platinum-based chemoradiotherapy, supported by phase 3 ADRIATIC study. Durvalumab reduced risk of death by 27% and disease progression by 24%, establishing a new standard of care.

The precision medicine market is projected to grow by USD 66.2 billion from 2024-2028, driven by the rising prevalence of chronic diseases and the increasing use of AI and ML. However, data privacy and security issues pose challenges. Key players include AbbVie Inc., Amgen Inc., AstraZeneca Plc, and others.

Pharmaceutical and biotech companies often change names to reflect mission and focus. Notable changes include J&J renaming Janssen to Johnson & Johnson Innovative Medicine, BeiGene becoming BeOne Medicines, Vaccitech rebranding as Barinthus Biotherapeutics, Cullinan Oncology shifting to Cullinan Therapeutics, and Eliem Therapeutics renaming to Climb Bio.

FDA grants Merck's sacituzumab tirumotecan (sac-TMT) breakthrough therapy designation for advanced non-squamous NSCLC with EGFR mutations, post-chemotherapy progression. This marks the first BTD for sac-TMT, an ADC developed with Kelun-Biotech, with Merck holding global marketing rights except in Greater China.

DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.

Novo Nordisk's CagriSema, combining semaglutide with cagrilintide, could be a breakthrough in obesity treatment. Analysts highlight amylin's role in satiety and hedonic eating, potentially improving weight reduction quality. Phase II results showed a 15.6% weight drop with CagriSema, and Phase III trials are ongoing. Competitors like Lilly and Zealand Pharma also advance amylin-based therapies, with promising early results.

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.